SCHEMBL660507

SCHEMBL660507

[2H]C([2H])([2H])c1nsc([C@@H]2CCCNC2)n1

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 7/20 0.36
CCNA2 P20248 7/20 0.36
CDK2 P24941 7/20 0.36
CCNA1 P78396 7/20 0.36
CHRM2 P08172 1/20 0.35
CHRM3 P20309 1/20 0.35
DPP4 P27487 1/20 0.34
BAZ2A Q9UIF9 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
MAP3K12 Q12852 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL662021 1.00 CHEK1 (0.36) CHEK1CCNA2CDK2CCNA1CHRM2
SCHEMBL662059 1.00 CHEK1 (0.36) CHEK1CCNA2CDK2CCNA1CHRM2
SCHEMBL661212 0.91 CHEK1 (0.34) CHEK1CCNA2CDK2CCNA1CHRM2
SCHEMBL662459 0.91 CHEK1 (0.34) CHEK1CCNA2CDK2CCNA1CHRM2
SCHEMBL659866 0.91 CHEK1 (0.34) CHEK1CCNA2CDK2CCNA1CHRM2
SCHEMBL661304 0.91 CHEK1 (0.34) CHEK1CCNA2CDK2CCNA1CHRM2
SCHEMBL662254 0.91 CHEK1 (0.34) CHEK1CCNA2CDK2CCNA1CHRM2
SCHEMBL662000 0.91 CHEK1 (0.34) CHEK1CCNA2CDK2CCNA1CHRM2
SCHEMBL661006 0.89 DPP4 (0.41) CHEK1CCNA2CDK2CCNA1DPP4
SCHEMBL659696 0.89 DPP4 (0.41) CHEK1CCNA2CDK2CCNA1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523944-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING Mithridion, Inc. (US) 2012-11-21 EP claimed
US-20120046273-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2012-02-23 US claimed
EP-2403340-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING Mithridion, Inc. (US) 2012-01-11 EP claimed
US-20110263613-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MAPLIGHT THERAPEUTICS, INC. 2011-10-27 US claimed
WO-2011085406-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2011-07-14 WO claimed
WO-2010102218-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2010-09-10 WO claimed
US-20180099956-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MITHRIDION, INC. 2018-04-12 US disclosed
US-20170313687-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating NEUROSOLIS INC (US) 2017-11-02 US disclosed
US-9738633-B2 Cognition enhancing compounds and compositions, methods of making, and methods of treating NEUROSOLIS, INC. (US) 2017-08-22 US disclosed
US-20160340348-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MAPLIGHT THERAPEUTICS, INC. 2016-11-24 US disclosed
US-9403806-B1 Cognition enhancing compounds and compositions, methods of making, and methods of treating NEUROSOLIS, INC. (US) 2016-08-02 US disclosed
US-20160199356-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MAPLIGHT THERAPEUTICS, INC. 2016-07-14 US disclosed
US-9174972-B2 Cognition enhancing compounds and compositions, methods of making, and methods of treating NEUROSOLIS, INC. (US) 2015-11-03 US disclosed
US-20130274299-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MAPLIGHT THERAPEUTICS, INC. 2013-10-17 US disclosed
EP-2523944-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING Mithridion, Inc. (US) 2012-11-21 EP disclosed
US-20120046273-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2012-02-23 US disclosed
EP-2403340-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING Mithridion, Inc. (US) 2012-01-11 EP disclosed
US-20110263613-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MAPLIGHT THERAPEUTICS, INC. 2011-10-27 US disclosed
WO-2011085406-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2011-07-14 WO disclosed
WO-2010102218-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340348-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating CHRM3, CHRM4, CHRM5 CHEK1 836/4885CCNA2 2883/4885CDK2 2066/4885
US-20120046273-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING CHRM3, CHRM4, CHRM5 CHEK1 1286/4885CCNA2 2660/4885CDK2 2499/4885
US-20130274299-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating CHRM3, CHRM4, CHRM5 CHEK1 836/4885CCNA2 2883/4885CDK2 2066/4885
US-20110263613-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING CHRM3, ACHE, CHRM4 CHEK1 626/4885CCNA2 2358/4885CDK2 1292/4885
US-20160199356-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating CHRM3, CHRM4, CHRM5 CHEK1 836/4885CCNA2 2883/4885CDK2 2066/4885
US-20180099956-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating CHRM3, CHRM4, CHRM5 CHEK1 836/4885CCNA2 2883/4885CDK2 2066/4885
US-20170313687-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating CHRM3, ACHE, CHRM4 CHEK1 626/4885CCNA2 2358/4885CDK2 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.